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ABSTRACT
Dual specificity phosphatase 6 (DUSP6) is a protein phosphatase that deactivates 
extracellular-signal-regulated kinase (ERK). Since the ovarian cancer biomarker 
human epididymis protein 4 (HE4) interacts with the ERK pathway, we sought to 
determine the relationship between DUSP6 and HE4 and elucidate DUSP6’s role in 
epithelial ovarian cancer (EOC). Viability assays revealed a significant decrease in 
cell viability with pharmacological inhibition of DUSP6 using (E/Z)-BCI hydrochloride 
in ovarian cancer cells treated with carboplatin or paclitaxel, compared to treatment 
with either agent alone. Quantitative PCR was used to evaluate levels of ERK pathway 
response genes to BCI in combination with recombinant HE4 (rHE4), carboplatin, and 
paclitaxel. Expression of EGR1, a promoter of apoptosis, was higher in cells co-treated 
with BCI and paclitaxel or carboplatin than in cells treated with chemotherapeutic 
agents alone, while expression of the proto-oncogene c-JUN was decreased with 
co-treatment. The effect of BCI on the expression of these two genes opposed that 
of rHE4. Pathway focused quantitative PCR also revealed suppression of ERBB3 in 
cells co-treated with BCI plus carboplatin or paclitaxel. Finally, expression levels of 
DUSP6 in EOC tissue were evaluated by immunohistochemistry, revealing significantly 
increased levels of DUSP6 in serous EOC tissue compared to adjacent normal tissue. 
A positive correlation between HE4 and DUSP6 levels was determined by Spearman 
Rank correlation. In conclusion, DUSP6 inhibition sensitizes ovarian cancer cells 
to chemotherapeutic agents and alters gene expression of ERK response genes, 
suggesting that DUSP6 could plausibly function as a novel therapeutic target to reduce 
chemoresistance in EOC.
INTRODUCTION
Ovarian cancer remains the most common and 
deadly gynecologic cancer, responsible for 240,000 
diagnoses and 152,000 deaths worldwide each year [1]. 
The 5-year survival rate remains at 35% [2], which is 
largely due to difficulty with early diagnosis, coupled 
with the frequency of chemoresistant recurrences [3]. 
A majority of epithelial ovarian cancer (EOC), the most 
common subtype of ovarian cancer, is initially responsive 
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to chemotherapy. However, once the disease recurs, 
chemoresistance inevitably develops and the patient 
eventually will succumb to their illness [4]. Therefore, 
there is a need for improved diagnostic approaches, as 
well as novel treatment targets to combat chemoresistance.
Human epididymis protein 4 (HE4) has been 
established as a novel clinical biomarker for EOC. 
Inclusion of preoperative serum HE4 levels into the 
diagnostic Risk of Ovarian Malignancy Algorithm 
(ROMA) results in demonstrably improved specificity 
and sensitivity in detection and monitoring of the disease 
over Cancer Antigen 125 (CA 125), pelvic sonography, 
and menopausal status alone [5]. Research has also 
shown its ability to support EOC pathogenesis, including 
the promotion of proliferation, chemoresistance, anti-
estrogen resistance, adhesion, invasion, and migration 
[6–17]. One oncogenic pathway that has consistently 
been shown to interact with HE4 in several studies is 
the extracellular signal regulated kinase (ERK) pathway. 
Several reports indicate that ERK activation is enhanced 
with HE4 treatment or overexpression, while ERK 
activation is conversely reduced with HE4 knockdown 
[9, 15, 16]. Our lab has revealed a complex response of 
ERK to recombinant HE4 treatment; specifically, we have 
observed downregulation of ERK phosphorylation at early 
time points following treatment with recombinant HE4, 
and its upregulation at later time points [9]. However, the 
precise nature of HE4’s interaction with the ERK pathway 
is not known in the context of EOC.
Dual specificity phosphatase 6 (DUSP6) is a key 
negative regulator of ERK signaling via dephosphorylation 
of ERK at serine/tyrosine residues. ERK activation 
upregulates gene expression of DUSP6, which promotes 
a negative feedback loop that suppresses ERK activation 
[18]. DUSP6 has differing effects on tumor progression 
depending on the tumor type. In pancreatic and lung 
cancer, DUSP6 is considered a tumor suppressor [19, 
20]. However, in glioblastoma and HER-2 positive breast 
cancer, it is upregulated and considered oncogenic [21, 
22]. In gastric cancer, DUSP6 inhibition can promote 
chemosensitivity [23], and it has also been characterized 
as a therapeutic target in acute lymphoblastic leukemia 
[24]. Although one ovarian cancer study suggested that 
DUSP6 acts as a tumor suppressor [25], the goal of the 
present study was to determine the potential relationship 
between HE4 and DUSP6 in the context of EOC.
RESULTS
HE4 regulates DUSP6 levels in ovarian cancer 
cells
To begin to elucidate the relationship between HE4 
and DUSP6, we examined DUSP6 mRNA and protein 
levels in SKOV3 ovarian cancer cells overexpressing 
HE4 (SKOV3-C1) compared to their null vector (NV) 
controls, which express low levels of HE4 naturally. 
These assays revealed increased DUSP6 mRNA (2.15-
fold, p=0.008) and protein (1.34-fold, p=0.007) in 
HE4 overexpressing SKOV3 cells (Figure 1A-1B). To 
determine if this upregulation of DUSP6 was dependent 
upon continued expression of HE4, HE4 was knocked 
down in SKOV3-C1 cells using CRISPR/Cas9. As 
expected, DUSP6 levels were concomitantly reduced in 
two independent knockdown clones (0.28-fold and 0.27–
fold, p=0.015 and p=9.2×10-4, respectively) (Figure 1C). 
Finally, treatment with recombinant HE4 (rHE4) at 4h 
and 24h increased DUSP6 levels in OVCAR8 (1.68-fold, 
p=ns, 1.37-fold, p=ns) and SKOV3 cells (1.57-fold, p=ns, 
2.39-fold, p=0.032)(Figure 1D). These results indicate that 
HE4 promotes DUSP6 expression in two human ovarian 
cancer cell lines.
Because both DUSP6 and HE4 are involved in ERK 
signaling, we next examined ERK phosphorylation in 
response to rHE4 treatment or DUSP6 inhibition with BCI, 
a cell permeable allosteric inhibitor of DUSP6 MAPK 
phosphatase activity. Interestingly, the upregulation of 
phospho-ERK by rHE4 was only observed sporadically in 
OVCAR8 and SKOV3 cells at 24 h (Figure 1E). We and 
others have reported activation of ERK by HE4 [9, 15, 
16]; specifically, we found that rHE4 suppressed phospho-
ERK levels at 1 and 4 h but increased them at 24 and 48 h 
[9]. While we did not perform a time course in the present 
study, the inconsistent results in this study suggest that the 
exact timing of phospho-ERK regulation by rHE4 may be 
variable.
Next, we observed an increase in phospho-ERK 
with BCI treatment in OVCAR8 and SKOV3 (4.03-fold 
and 2.45-fold, p=n/s and p=0.043, respectively), as would 
be expected if the negative regulation of ERK by DUSP6 
is being suppressed (Figure 1E). Finally, co-treatment with 
BCI and rHE4 resulted in upregulation of phospho-ERK 
in OVCAR8 and SKOV3 (5.78-fold and 2.80-fold, p= 
n/s and p=0.019, respectively). In addition, there was a 
general positive relationship between phospho-ERK and 
HE4 levels, corroborating a positive relationship between 
activation of ERK signaling and intracellular HE4 levels 
(Figure 1E). We further confirmed an upregulation of 
HE4 by BCI at 24 h in OVCAR8 and SKOV3 (2.05-fold, 
p=.001, 2.28-fold, p=0.041) (Figure 1F).
Furthermore, we determined the effect of 
2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-
3,4-difluorobenzamide, a highly specific inhibitor of 
MKK1 and the ERK pathway, on DUSP6 and HE4 levels. 
ERK inhibition downregulated DUSP6 in OVCAR8 and 
SKOV3 cells, which was expected since ERK is known to 
positively regulate DUSP6 expression to create a negative 
feedback loop on ERK activation (0.69-fold and 0.42–fold, 
p=0.016 and p=0.006 , respectively). In addition, a small 
but significant increase in HE4 levels was also observed 
in OVCAR8 and SKOV3 cells treated with the ERK 
inhibitor (1.18-fold and 1.22–fold, p=0.004 and p=0.009, 
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respectively) (Figure 1G). The upregulation of HE4 with 
ERK inhibition was contrary to our expectations that ERK 
inhibition would suppress HE4 levels, since we observed in 
a previous study that cells treated with recombinant human 
EGF increased HE4 levels following ERK activation 
[14]. We hypothesize that there may be a compensatory 
upregulation of HE4 via other mechanisms following 
ERK inhibition. Collectively, these results highlight that 
HE4 positively regulates DUSP6 levels in ovarian cancer 
cells, and both proteins regulate ERK signaling in time-
dependent manners. A working model for the relationship 
between HE4, DUSP6, and ERK signaling is outlined in 
Figure 1H. Triplicate western blots from which statistics 
were obtained can be seen in Supplementary Figure 1.
Figure 1: HE4 regulates DUSP6 levels in ovarian cancer cells (A). qPCR revealed upregulation of DUSP6 mRNA levels in 
SKOV3 cells overexpressing HE4 (C1) compared to null vector (NV) counterparts. (B) Western blot indicated that DUSP6 levels were 
upregulated in SKOV3-C1 cells compared to SKOV3-NV cells. (C) qPCR revealed downregulation of DUSP6 mRNA levels in two unique 
clones of SKOV3 cells with stable CRISPR-mediated HE4 knockdown. (D) Western blot showed that DUSP6 levels were upregulated 
with rHE4 treatment in OVCAR8 and SKOV3 cells. (E) Western blot showed that BCI treatment increased HE4 and activated ERK levels 
(+/+ refers to cells co-treated with BCI and rHE4). (F) Western blot showed that BCI increased phospho-ERK and HE4 levels in OVCAR8 
and SKOV3 cells. (G) Western blot revealed that ERK inhibition downregulated DUSP6 and slightly increased HE4 levels. (H) Working 
model for interaction of HE4 and DUSP6 with the ERK pathway. Activated ERK is known to upregulate DUSP6 mRNA; DUSP6 then 
suppresses ERK activation in a negative feedback loop, while the DUSP6 inhibitor BCI reverses this effect. Also as expected, inhibition 
of the ERK pathway downregulated DUSP6 levels; contrary to expectations, a slight increase was seen in HE4 levels. However, phospho-
ERK levels appear to positively associate with HE4, suggesting a positive relationship between these proteins. This idea is reinforced by 
studies showing that HE4 upregulates phospho-ERK, which may occur in a time- or context-dependent manner. Error bars for all graphs 
represent standard deviation of ≥3 biological replicates. *p<0.05, **p<0.005, ***p<0.0005, ****p<0.00005.
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Inhibition of DUSP6 sensitizes ovarian cancer 
cells to chemotherapeutic drugs
Next, we sought to determine the function of DUSP6 
in ovarian cancer cells. Since HE4 is known to promote 
chemosresistance in vitro, and HE4 is associated with poor 
chemoresponse in EOC patients [9], we treated SKOV3 
and OVCAR8 cells with a DUSP6 inhibitor (BCI) alone or 
in combination with paclitaxel or carboplatin, the standard 
of care chemotherapeutic agents in EOC. A dose response 
curve was generated to determine an optimal dose of BCI 
for all subsequent experiments (Supplementary Figure 2).
Treatment of cells with 3.75 µM BCI alone resulted 
in a small but significant reduction in cell viability relative 
to control as determined by 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) (MTS) assay – 86.3% (p=0.007) and 84.7% 
(p=.004) in OVCAR8 and SKOV3, respectively. In both 
cell lines, co-treatment with BCI and 100 µM carboplatin 
resulted in a statistically significant synergistic effect 
on cytotoxicity compared to either treatment alone. 
Carboplatin alone treatment resulted in 88.8% (p=0.002) 
and 86.8% (p=4.9×10-4) survival in OVCAR8 and SKOV3 
cells, respectively, while BCI with carboplatin resulted in 
33.3% (p=2.51×10-7) and 50.1% (p=5.46×10-7) survival in 
OVCAR8 and SKOV3 cells, respectively. The difference 
between carboplatin alone and carboplatin with BCI was 
also statistically significant in OVCAR8 and SKOV3 
(p=1.78×10-7 and 3.25×10-6, respectively).
Likewise, significantly more death was noted 
with BCI and 10 nM paclitaxel treatment, with survival 
of 51.4% in OVCAR8 (p=1.73×10-6) and 51.3% in 
SKOV3 (p=9.37×10-7) with paclitaxel alone, and 25.4% 
(p=1.8×10-6) and 45.0% (p=9.66×10-7) with the addition 
of BCI with paclitaxel. The difference between paclitaxel 
alone and paclitaxel with BCI was statistically significant 
in OVCAR8 and SKOV3 (p=1.1×10-4 and 0.022, 
respectively) (Figure 2A-2B). In order to verify the results 
at multiple doses of carboplatin, cells were treated with 
3.75 uM BCI with varying doses of carboplatin (100, 250, 
500 µM). At all doses tested, combinatorial treatment 
with BCI and carboplatin resulted in significantly reduced 
viability of OVCAR8 and SKOV3 cells compared to 
carboplatin alone (Figure 2C-2D).
DUSP6 inhibition alters expression of ERK 
pathway responsive genes
In order to determine how regulation of ERK 
signaling by BCI versus rHE4 might affect downstream 
gene expression, we treated cells with BCI alone or in 
combination with rHE4, paclitaxel, or carboplatin, and 
examined expression of the ERK pathway response genes 
EGR1 and c-JUN. EGR1 is a transcription factor involved 
in promoting apoptosis in many cancers [26–29], and is 
involved in cisplatin resistance in esophageal and ovarian 
cancer cells [29, 30]. We have previously shown that HE4 
suppresses cisplatin-induced EGR1 gene upregulation 
in SKOV3 cells [9]. On the other hand, c-JUN is a 
transcription factor involved in promoting cell survival 
and growth, and is associated with resistance to platinum-
based chemotherapy [31].
Treatment with BCI modestly upregulated EGR1 
expression by 1.48-fold (p=0.022) and 1.63-fold (p=1.2×10-
4) in OVCAR8 and SKOV3 cells, respectively. Conversely, 
treatment with rHE4 resulted in 0.56-fold (p=0.0016) and 
0.55-fold (p=2.5×10-4) reduced EGR1 expression relative 
to control in OVCAR8 and SKOV3, respectively—a result 
that is in agreement with our previous study showing HE4 
suppresses cisplatin-mediated upregulation of EGR1 [9]. 
The effect of BCI on EGR1 expression was more apparent 
with rHE4 co-treatment, where it significantly reversed the 
downregulation of EGR1 by rHE4 in OVCAR8 (p=0.016) 
and SKOV3 (p=0.026). Furthermore, co-treatment with BCI 
and either paclitaxel or carboplatin upregulated expression 
of EGR1 compared to treatment with either chemo drug 
alone. EGR1 levels were increased by 2.35-fold with 
paclitaxel and BCI versus 1.38-fold with paclitaxel alone 
(p=0.005). Although the response was not as robust with 
paclitaxel, a similar trend was observed with carboplatin 
co-treatment (Figure 3A-3B).
Conversely, treatment with BCI resulted in 0.86-fold 
(n/s) and 0.78-fold (p=0.004) reduced c-JUN levels relative 
to control in OVCAR8 and SKOV3 cells, respectively, 
while rHE4 upregulated c-JUN by 1.32-fold (n/s) and 1.60-
fold (n/s). Again, co-treatment with BCI and rHE4 reversed 
the upregulation of c-JUN by rHE4. We also observed a 
decrease in c-JUN levels in BCI and chemotherapy treated 
groups compared to chemotherapy alone groups, although 
only the carboplatin versus BCI/carboplatin result in 
SKOV3 cells reached the cutoff for significance (p=0.039; 
Figure 3C-3D). Collectively, these results show that BCI 
opposes the effects of HE4 on EGR1 and c-JUN expression, 
and promotes EGR1 expression while suppressing c-JUN 
expression in cells exposed to chemotherapeutic drugs.
DUSP6 inhibition alters ovarian cancer cells’ 
chemotherapy response genomic profile
In order to gain a further understanding of the 
effect of BCI combinatorial treatment on gene expression 
profiles, RNA from SKOV3 cells treated with vehicle, 
BCI, carboplatin, BCI/carboplatin, paclitaxel, and BCI/
paclitaxel was used on a pathway-focused qPCR array 
for Human Cancer Drug Resistance (Qiagen, PAHS-
004Z). The heat map represents the similarities in 
profiles between carboplatin and BCI. The carboplatin/
BCI profile shares similarities with both the carboplatin 
alone or BCI alone profile. The paclitaxel gene profile 
stands out as unique, while BCI/paclitaxel shows a mixed 
expression signature between BCI alone and paclitaxel 
alone treatments (Figure 4). Collectively, the genomic 
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analysis of cells treated with BCI and chemotherapy 
agents reveal that BCI promotes similar chemo-response 
and cell death pathways as carboplatin. However, a 
more in-depth analysis of the specific genes regulated 
by each of these treatments revealed differences that 
may contribute to the role of DUSP6 in the increased 
chemosensitivity of these cells.
The top five upregulated and downregulated genes 
from each treatment comparison are outlined in Table 
1. We observed a very similar expression profile with 
BCI alone and carboplatin alone treatments, with the 
top increased mRNAs compared to control with either 
treatment being ELK1, GAPDH, ERBB2, ABCC1, 
BCL2L1, and PPARD, and the most reduced mRNAs 
including Cytochrome P450 family genes, as well 
as CDKN2A and AR. BCI/carboplatin co-treatment 
also produced similar effects on gene expression as 
carboplatin alone or BCI alone. The top genes upre- 
gulated in all three groups relative to control were ELK1, 
GAPDH, ERBB2, ABCC1, BCL2L1, and PPARD. 
Conversely, ERBB3 and RARB were the genes most 
downregulated with BCI/carboplatin co-treatment 
compared to control, which differed from BCI alone or 
carboplatin alone treatments.
Paclitaxel treatment alone produced a unique 
gene expression signature, with top genes upregulated 
compared to control being RARA, CCND1, BCL2L1, 
NFKB2, and NFKBIB. The most downregulated genes 
were RARB, ATM, ARNT, BCL2, and NAT2. BCI and 
paclitaxel co-treatment produced a mixed signature, with 
Figure 2: Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic drugs. OVCAR8 cells (A) and SKOV3 
cells (B) exhibited reduced viability by MTS assay when co-treated for 24 h with the DUSP6 inhibitor BCI and either paclitaxel or 
carboplatin compared to either chemotherapeutic agent alone. OVCAR8 cells (C) and SKOV3 cells (D) were treated with various doses 
of carboplatin alone or in combination with 3.75 uM BCI for 24 h. Cell viability was measured with MTS assay. A synergistic effect was 
observed with the addition of BCI to carboplatin at all doses tested. Error bars represent standard deviation from ≥3 biological replicates. 
For clarity, only significance between Ctrl vs. BCI and single agent chemo vs. BCI+chemo are indicated on the graph. Error bars represent 
standard deviation of ≥3 biological replicates. *p<0.05, **p<0.005; ***p<.0005, ****p<.00005.
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Figure 4: DUSP6 inhibition alters ovarian cancer cells’ chemotherapy response genomic profile. Heatmap of gene 
expression (analyzed by Human Cancer Drug Resistance pathway focused qPCR array) in SKOV3 cells treated with BCI, carboplatin, 
paclitaxel, or chemotherapy in combination with BCI. Clustering, performed by the Qiagen GeneGlobe Data Analysis Center, indicates 
groups with most similarity between each other.
Figure 3: DUSP6 inhibition alters expression of ERK pathway responsive genes. OVCAR8 and SKOV3 cells were treated 
with BCI, carboplatin, BCI+carboplatin, paclitaxel, or BCI+paclitaxel for 24 h and qPCR was performed. (A) BCI opposed the effect of 
rHE4 on EGR1 levels in OVCAR8 cells, and EGR1 mRNA levels were higher in cells co-treated with BCI and chemotherapeutic drugs 
than in cells treated with chemotherapy alone. (B) BCI opposed the effect of rHE4 on c-JUN levels in OVCAR8 cells, and c-JUN mRNA 
levels were lower in cells co-treated with BCI and chemotherapeutic drugs than in cells treated with chemotherapy alone. (C) BCI opposed 
the effect of rHE4 on EGR1 levels in SKOV3 cells, and EGR1 mRNA levels were higher in cells co-treated with BCI and chemotherapeutic 
drugs than in cells treated with chemotherapy alone. (D) BCI opposed the effect of rHE4 on c-JUN levels in SKOV3 cells, and c-JUN 
mRNA levels were lower in cells co-treated with BCI and chemotherapeutic drugs than in cells treated with chemotherapy alone. Error bars 
represent standard deviation of n≥3 independent experiments. *p<.05; **p<.005; ***p<.0005; ***p<.00005.
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ELK1, ABCC1, GAPDH, NFKBIB, and BCL2L1 being 
the most upregulated genes, and RARB, XPA, APC, 
CYP1A1, and MSH2 being the most downregulated.
Further comparisons were performed between 
carboplatin or paclitaxel alone and in combination with 
BCI. The differences in upregulated genes between BCI/
Table 1: Most differentially expressed genes from pathway focused qPCR array
Group Comparison Gene Fold-change (up) Gene Fold-change (down)
BCI vs. Ctrl ELK1 29.2 CYP2E1 -2.42
GAPDH 28.47 CYP1A2 -2.42
ERBB2 23.48 CDKN2A -2.42
ABCC1 23.02 AR -2.42
BCL2L1 18.04 ABCB1 -2.42
Carbo vs. Ctrl ABCC1 27.74 CYP3A4 -2.76
ELK1 27.47 CYP2B6 -2.76
GAPDH 26.35 CDKN2A -2.76
RARG 20.72 SULT1E1 -2.76
ERBB2 19.01 AR -2.76
BCI/Carbo vs. Ctrl ELK1 33.41 ERBB3 -3.18
GAPDH 27.79 RARB -2.70
ABCC1 25.27 XPA -2.08
ERBB2 24.92
PPARD 19.00
Pax vs. Ctrl RARA 11.16 RARB -5.48
CCND1 9.64 ATM -5.19
BCL2L1 9.46 ARNT -3.53
NFKB2 8.90 BCL2 -3.17
NFKBIB 8.73 NAT2 -2.88
BCI/Pax vs. Ctrl ELK1 44.81 RARB -5.53
ABCC1 25.65 XPA -3.79
GAPDH 25.28 APC -2.52
NFKBIB 24.27 CYP1A1 -2.38
BCL2L1 21.26 MSH2 -2.13
BCI/Carbo vs. Carbo CYP2C8 2.57 ERBB3 -15.13










carboplatin and carboplatin alone were modest and 
comprised Cytochrome P450 family genes. Only two 
genes were downregulated in BCI/carboplatin versus 
carboplatin alone, and of those, only ERBB3 showed robust 
downregulation. The differences in upregulated genes 
between paclitaxel/BCI and paclitaxel alone reflected the 
addition of BCI to paclitaxel. There was robust upregulation 
of ELK1, ERBB2, RARG, GAPDH, and RELB with co-
treatment, which was not noted with paclitaxel treatment 
alone, as well as modest downregulation of ERBB3. A 
similar suppression of ERBB3 was observed in OVCAR8 
cells treated with BCI and chemotherapeutic drugs 
(Supplementary Figure 3). The complete results of the 
qPCR array can be found in Supplementary Dataset 1.
DUSP6 levels are upregulated in EOC tissue 
compared to adjacent normal tissue, and 
correlate with HE4 tissue levels
To verify the clinical relevance of our findings, 
we performed immunohistochemistry of DUSP6 in an 
EOC tumor microarray and compared levels in serous 
adenocarcinoma samples (n=40) to levels in normal 
adjacent tissue (NAT; n=7). Mean intensity of DUSP6 
was 573 (+/− 19.6) in EOC samples, and 432 (+/−24.5) 
in NAT (p=0.0027). Moreover, maximal intensity was 
significantly greater in serous EOC samples than NAT. 
Maximum intensity was 1632 (+/−109.6) for EOC and 
900 (+/−110.3) for NAT (p=0.0045), indicating that some 
areas of EOC exhibited particularly strong staining for 
DUSP6 (Figure 5A). Representative images are shown in 
Figure 5B.
In order to determine if a correlation exists 
between HE4 levels and DUSP6 levels in EOC, we co-
stained for both proteins in the ovarian tissue microarray, 
and calculated correlations for mean intensity values 
and integrated optical density (IOD). Spearman Rank 
correlation test revealed a positive correlation between 
DUSP6 and HE4 mean intensities (R=0.45, p=0.0038) 
and IOD values (R=0.64, p=1.0×10-5) (Figure 5C-5D). 
Together, these results suggest that DUSP6 may be 
involved in promoting tumorigenesis and chemoresistance 
in EOC, and highlight a relationship between HE4 and 
DUSP6 in vitro and in EOC.
DISCUSSION
In this study, we found that HE4 promotes 
upregulation of DUSP6 in ovarian cancer cells, and that 
levels of these proteins positively correlate in EOC tissue. 
We also determined that inhibition of DUSP6 promotes 
chemosensitivity of two different ovarian cancer cell lines, 
which coincided with increased expression of pro-apoptotic 
EGR1, and reduced expression of oncogenic c-JUN. 
Lastly, we examined the genomic signature of cells treated 
with a DUSP6 inhibitor alone or in combination with the 
chemotherapeutic drugs carboplatin or paclitaxel, and found 
a reduction in ERBB3 mRNA with BCI and chemotherapy 
co-treatment compared to chemotherapy alone.
The nature of the relationship between HE4 and 
DUSP6 was revealed by examining the effect of DUSP6 
inhibition and ERK inhibition on HE4 and DUSP6 levels. 
Counter to our expectations, inhibition of DUSP6 with 
BCI actually resulted in an upregulation of HE4. This 
may be explained by BCI-mediated upregulation of 
phospho-ERK leading to an upregulation of HE4, since 
our previous published data showed that activation of 
the epidermal growth factor receptor (EGFR) signaling 
pathway leads to an increase in HE4 [14]. However, it 
does highlight the fact that activation of phospho-ERK 
via different mechanisms may produce differing effects 
on both gene expression and cell behavior. Moreover, 
while ERK inhibition produced an expected suppression 
of DUSP6 levels, it actually increased HE4 levels, again 
highlighting an as yet unexplained relationship between 
DUSP6, HE4, and ERK signaling. There are likely many 
time- and context-dependent pathways and feedback 
mechanisms that play a role in the regulation of HE4 and 
DUSP6.
The two ERK responsive genes we characterized 
show opposite expression patterns with BCI treatment. 
EGR1 is activated by ERK via the transcription factor 
ELK-1, and EGR1 is itself a transcription factor that 
activates expression of genes regulating proliferation, 
differentiation, and apoptosis [32, 33]. A previous study 
by our lab showed that HE4 overexpression in SKOV3 
cells suppresses cisplatin-mediated upregulation of 
EGR1 [9]. In the present study, we observed that HE4 
downregulated EGR1 expression, which is consistent 
with these previous results. Conversely, BCI treatment 
opposed the effect of rHE4 on EGR1 expression. c-JUN, 
which is also an ERK responsive gene, was regulated 
in the opposite direction as EGR1. rHE4 treatment 
upregulated expression of c-JUN, which is consistent with 
its role as a promoter of tumor growth and proliferation 
[6, 7, 13, 14, 16]. Meanwhile, BCI again opposed this 
effect in BCI and rHE4 co-treated cells. Furthermore, BCI 
suppressed chemotherapy-mediated increases in c-JUN 
levels. The effects of BCI on EGR1 and c-JUN together 
may contribute to the overall increased efficacy of BCI 
and chemotherapy treatment over chemotherapy alone, 
and could explain the opposing effects of BCI and HE4 
on chemotherapy response.
The pathway focused qPCR array revealed further 
differences in gene expression profiles between the different 
treatment groups. As expected, ELK1, an ERK response 
gene that encodes for a transcription factor that regulates 
ERK response genes such as EGR1, was upregulated with 
BCI treatment, as well as carboplatin alone. Co-treatment 
with BCI and carboplatin resulted in similar expression 
profiles as either treatment alone, save for a robust decrease 
in ERBB3 gene expression with co-treatment compared to 
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carboplatin treatment alone, suggesting that downregulation 
of ERBB3 may also be involved in the increased efficacy of 
co-treatment. ERBB3 (HER3) is a type 1 receptor tyrosine 
kinase (RTK) that lacks intrinsic kinase function, and 
must dimerize with another ERBB receptor—particularly 
ERBB2 (HER2)—to activate signaling. ERBB3 is as a 
potent partner for and may even be required to maintain the 
oncogenic activity of ERBB2, which has no known ligand 
[34–41]. Upon ERBB3 ligand binding and subsequent 
hetero-dimerization with ERBB2, diverse signaling 
pathways may be activated, such as the PI3K/AKT pathway, 
which is heavily involved in promoting chemoresistance in 
many cancers [42–44]. Most importantly, a role for ERBB3 
has been described in promoting chemoresistance and 
tumor progression in ovarian cancer [45–47].
In contrast to the effects of carboplatin or BCI on 
SKOV3 cells, paclitaxel elicited a markedly different 
expression profile. Combinatorial treatment with BCI 
and paclitaxel produced increases in BCI regulated genes 
such as ELK1 and ERBB2 compared to paclitaxel alone, 
and also elicited a small reduction in ERBB3 levels as 
well. Therefore, it is possible that the increase in cell 
death elicited by co-treatment with paclitaxel and BCI 
may occur via the upregulation of certain BCI-regulated 
genes, as well as the downregulation of ERBB3. Further 
studies are required to elucidate the exact involvement 
of ERBB3, ELK1 and its downstream effectors such as 
EGR1, as well as c-JUN, on the synergistic effect of BCI 
on cytotoxicity. It is important to mention that BCI also 
possesses activity against another DUSP-family member, 
DUSP1 [48]. DUSP1 is a class -1 DUSP that has selectivity 
for JNK, ERK, and p38. DUSP1 possesses the strongest 
selectivity for JNK, unlike DUSP6, which only possesses 
substrate selectivity for ERK [49]. Therefore, we cannot 
discount that the activity of BCI on DUSP1 could also be 
influencing phospho-ERK signaling and chemoresponse. 
However, since we are primarily interested in the clinical 
relevance of a small molecule inhibitor, we chose to use 
BCI in our study despite this potential off target effect.
The specific role of DUSP6 in the context EOC 
is not well established. One report showed that DUSP6 
appears to function as a tumor suppressor in EOC [25], but 
our results suggest the opposite effect. Therefore, further 
study is needed to fully elucidate the role of DUSP6 and 
Figure 5: DUSP6 levels are higher in EOC tissue than normal adjacent tissue, and correlate with HE4 tissue levels (A). 
DUSP6 mean and maximum intensity staining is higher in serous EOC tissue (n=40) than in normal adjacent tissue (NAT) (n=7). Error bars 
represent standard deviation. **p<0.005 (B) Representative images of NAT and serous EOC DUSP6 staining. (C) Correlation of DUSP6 and 
HE4 mean intensity. (D) Correlation of DUSP6 and HE4 integrated optical density (IOD).
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determine if its function is context dependent. In general, 
DUSP6 remains an interesting protein in that it has 
opposing roles in different tumor types. In some cancers, it 
appears to act as a tumor suppressor, while in others it acts 
to promote tumorigenesis and aggressive behavior [20–25]. 
Our results are consistent with a recent study by Wu et al. 
(2018) showing DUSP6 involvement in cisplatin resistance 
in gastric cancer [23]. The authors observed an increase in 
phospho-ERK with BCI treatment, but a downregulation 
of the ERK-response genes RPS6KA1, EGR1, MMP2, 
MMP9, MYC, and ELK3, again showing that activation 
of ERK does not automatically lead to activation of its 
target genes. In our study, we observed different effects 
of DUSP6 inhibition on ERK-response genes depending 
upon gene function—namely, upregulation of EGR1 and 
downregulation of c-JUN. Furthermore, Wu et al. found 
that BCI treatment enhanced cisplatin sensitivity in gastric 
cancer cells and in vivo xenografts. Collectively, our study 
and the one by Wu et al. illustrate that the relationship 
between ERK activation and downstream gene activation 
is not straightforward, and appears to be highly context-
dependent. Therefore, although BCI serves to increase 
ERK activation and increase HE4 levels, it has differing 
effects on ERK response genes, which can potentially be 
manipulated to enhance chemotherapy efficacy.
In conclusion, this study highlights a novel function 
of DUSP6 in EOC, and reveals that it may be involved 
in regulating chemoresponse. Targeting HE4 and/or 
DUSP6 in EOC may be an effective method of reversing 
chemoresistance and improving long-term response rates 
in selected patient populations.
MATERIALS AND METHODS
Cell culture and treatments
SKOV3 and OVCAR8 cells were obtained from 
American Type Culture Collection (ATCC) and kept 
at low passage in Dulbecco Modified Eagle Medium 
(DMEM) with 10% fetal bovine serum and 1% penicillin/
streptomycin, in a humidified incubator at 37°C/5% 
CO2. Cells were plated at sub-confluent density the day 
before treatments. Cells were treated with 3.75 µM BCI 
(Sigma Aldrich, B4313), 20 nM recombinant HE4 (My 
BioSource, MBS355616 or Raybiotech, 230-30001-10), 
100 µM carboplatin (Sigma Aldrich, C2538), 10 nM 
paclitaxel (Sigma Aldrich, T7402), or control treatments 
(0.037% DMSO and/or H20) for indicated time points. 
SKOV3-NV, SKOV3-C1, and SKOV3-C1-CRISPR cell 
lines were generated as previously described [9, 14].
Western Blot
Western blot was performed as previously described 
[10]. GAPDH was used as a loading control. Antibodies 
and dilutions used are as follows:
 MKP-3 (DUSP6) (Santa Cruz, sc-377070; 1:100 or 
Novus Biologicals, NBP2-67320, 1:50)
HE4 (Origene, TA307787, 1:2000)
GAPDH (Cell Signaling, 2118, 1:2000)
 Phospho-p44/42 (ERK1/2) (Cell Signaling, 9101, 
1:2000)
Densitometry
Image J “analyze gel” function was used to perform 
densitometry analysis of western blot images in 8-bit TIFF 
format. Band densities were normalized to GAPDH, and 
the control was set to 1 for plotted graphs.
Quantitative RT-PCR
Quantitative RT-PCR was performed as previously 
described [10]. Validated primers for DUSP6, EGR1, 
c-JUN, and ERBB3 were purchased from https://
www.realtimeprimers.com. Custom primer sequences 
(Invitrogen) are as follows:
18s rRNA (F) – CCG CGG TTC TAT TTT GTT GG
 18s rRNA (R) – GGC GCT CCC TCT TAA TCA 
TG
HE4 (F) – CTG CCC CCA GGT GAA CAT TA
HE4 (R) – CCA TTG CGG CAG CAT TTC AT
qPCR Array
One set of SKOV3 cell RNA from the experiment 
in Figure 3 was used for the qPCR array (control, 
BCI, carboplatin, BCI+carboplatin, paclitaxel, and 
BCI+paclitaxel). RNA was reverse transcribed using the 
RT2 First Strand Kit (Qiagen, 330401), and cDNA was 
then added with SYBR green mastermix (Qiagen, 330504) 
to 96-well RT2 Profiler Human Cancer Drug Resistance 
PCR Array plates (Qiagen, PAHS-004Z), according to the 
manufacturer’s instructions. The plates were run on an 
ABI 7500 qPCR machine, with 10 min at 95 °C, and 40 
cycles of 15s at 95 °C and 1 min at 60 °C. An automated 
baseline was used, with thresholds manually adjusted 
to remain constant across all plates. Data was analyzed 
using the GeneGlobe Data Analysis Center at https://www.
qiagen.com. The housekeeping gene RPLP0 was used for 
normalization, which was automatically selected by the 
software based on stable expression between treatments. 
Calculations of relative expression levels were performed 
using the using the ΔΔCt method All samples passed 
quality control standards (array reproducibility, RT 
efficiency, and genomic DNA contamination).
Cell viability assay
Cells were seeded at 2000 cells/well in 96-well 
plates, and treated as described above. After 24 h, cell 
viability assays were performed by adding 10 µl/well of 
CellTiter 96® Aqueous One Solution Cell Proliferation 
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MTS Assay (Promega, G3580), incubating at 37°C/5% 
CO2 for 2 h, and reading absorbance at 492 nm. Results 
are displayed as percent survival relative to vehicle treated 
cells.
Immunohistochemistry
Immunohistochemical staining of an ovarian cancer 
microarray (US Biomax, OV802a) was performed as 
previously described [50], using antibodies for HE4 
(Santa Cruz, sc-293473) and DUSP6 (MyBioSource, 
MBS8516662). Confocal microscopy was performed by 
an independent imaging technician at the Rhode Island 
Hospital Digital Imaging Core Facility with a Nikon C1si 
confocal (Nikon Inc. Mellville, NY, USA). Two to three 
fields/sample were randomly selected based on DAPI 
staining, and minimum, mean, and maximum gray values 
(pixels) were determined for each field. For the tumor 
microarray, normal adjacent tissues were used to set the 
threshold for positive staining. Integrated optical density 
(IOD) was calculated in serous samples using the mean 
values multiplied by the total area.
Statistics
Where statistics are shown, n≥3 biological 
replicates. p-values from quantitative PCR, MTS assay, 
and western blots were determined by unpaired, 1-tailed 
Student t-test. For correlation analysis, Spearman rank test 
was used to determine R value and corresponding p-values 
using the calculators at https://www.socscistatistics.com. 
Differences were considered statistically significant when 
p < 0.05.
Abbreviations
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